On the basis of favorable results from previous trials, current international guidelines for the management of T2DM recommend the use of SGLT2 inhibitors in patients with atherosclerotic cardiovascular disease, heart failure, and renal disease6. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.